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differences in conventional DVT risk factors and no dif-
ferences in the aggregate number of risk factors. In addi-
tion, the anatomic distribution of DVT has been reported
to be the same in men as in women.1
Mortality rates are as high as 10% within the first
month after surgery, caused primarily by pulmonary
embolism, myocardial infarction, or stroke.2,3 Despite the
use of central neural block anesthetic techniques and
low–molecular-weight heparin prophylaxis, 20% to 50% of
patients for TKA or hip arthroplasty still have DVT
develop.4-6 Currently, the diagnosis of DVT relies on
nuclear radiography, contrast venography, or ultrasound
scan techniques; the first two are associated with invasive
risks and may also be investigator-dependent in their diag-
nostic quality. Thus, there is a need for a simple, safe, and
effective screening assay that could help formulate an ear-
lier appropriate treatment regimen that would benefit a
large proportion of patients who undergo major orthope-
dic surgery. It is envisioned further that if risk assessment
(for DVT) could be continued for several weeks after
surgery among the patients for TKA, such benefits of
treatment could well be truly maximized.
Platelet activation has been associated with the devel-
opment of venous thrombosis. Platelet activation, the trig-
Thrombotic complication is one of the leading causes
of fatality and life-threatening events after major orthope-
dic surgery. Advanced age, obesity, malignant disease, con-
gestive heart failure, acute myocardial infarction, prior
deep vein thrombosis (DVT) or pulmonary thromboem-
bolism, estrogen use, and immobilization have been iden-
tified as perioperative thrombotic risk factors in total knee
arthroplasty (TKA). However, between male and female
patients, it is generally known that there are no significant
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Background: Deep vein thrombosis (DVT) remains a leading cause of postoperative morbidity and mortality in patients
who undergo total knee arthroplasty (TKA). Although patients with previous thrombotic episodes are inherently at a
higher risk for subsequent episodes of DVT, it remains difficult to predict such an occurrence and to make a diagnosis
in early stages. One potentially useful assay that can be used in the determination of changes of coagulation among
patients who undergo arthroplasty is platelet activation. The goal of this study was to establish a predictive value for
DVT with measurement of P-selectin levels that could help in planning appropriate perioperative management strate-
gies for patients at high risk for DVT.
Methods: A total of 52 patients who underwent TKA with general anesthesia underwent contrast venography on the
5th postoperative day. Platelet activation before and after operation was measured with platelet surface expression of
P-selectin with flow cytometry in these two groups of patients for TKA. None of the patients underwent any antico-
agulation therapy.
Results: Nineteen of the 52 patients for TKA showed radiologic evidence of DVT, whereas 33 patients for TKA had no
radiologic signs of DVT. There was no difference in platelet activation at baseline, which was 1 hour before induction
of anesthesia, between the two groups (P > .05) as measured with P-selectin assays. Differences were noted between the
two groups on the 5th day after operation, wherein P-selectin was expressed in only 2.72% ± 0.9% (mean ± standard
deviation) of platelets in patients for TKA with healthy venogram results. This differed significantly from platelets in
patients for TKA with DVT, who had P-selectin expression of 6.56% ± 3.1% (mean ± standard deviation; P < .01).
Sensitivity for the diagnosis of DVT with P-selectin assay was calculated to be 74%, and specificity was found to be 94%.
Conclusion: The findings showed that radiologically confirmed DVT in patients for TKA surgery with general anes-
thesia is associated with an elevated number of activated platelets. Perioperative assessment of P-selectin may predict
the early onset of DVT in patients who undergo high risk surgical procedures like TKA. This laboratory assay may help
prevent the occurrence of the fatal events caused by DVT with use of early therapeutic intervention, such as hepariniza-
tion. (J Vasc Surg 2002;35:707-12.)
gering of coagulation cascade, and the blunting of endoge-
nous fibrinolytic activity have been reported to be involved
in the changes of coagulation in patients who undergo
knee arthroplasty.7 In the case of platelets, flow cytometry
has been shown to be an effective tool for the determina-
tion of platelet function, for instance, that of platelet acti-
vation.8,9 P-selectin (CD62p) is a molecule found in the
storage granules of platelets and in the Weible–Palade bod-
ies of endothelial cells. It is involved in the binding of
leukocytes to the endothelium or the platelets to mono-
cytes in areas of inflammation. One of the changes that
occurs at the platelet surface during activation is the fusion
of the -granule membrane with the plasma membrane. As
a result of this process, P-selectin (CD62p) becomes
expressed on the platelet surface, and this expression has
been shown to be a useful marker for platelet activation. Its
surface expression correlates with the release of -granule
content, and it is not reinternalized after secretion. In this
study, we propose that platelet abnormalities or changes in
platelet activation may serve as important markers, the
appearance of which could herald the occurrence of post-
operative DVT in patients who undergo TKA. Specifically,
the goal of this study was to prospectively investigate
whether the changes in the levels of P-selectin (platelet
activation–dependent antigens) expression can be used as
“early markers” to determine a higher risk or susceptibility
for development of DVT during TKA or even a few days
or weeks after TKA with general anesthesia. 
METHODS
Recruitment of study participants. After the insti-
tutional technical and ethical review board approval and
informed consent were obtained, 52 adult female patients,
classified as American Society of Anesthesiologists physical
status 1 to 3, who were scheduled for TKA with general
anesthesia were enrolled in this study (Appendix, online
only). Exclusion criteria included: 1, age younger than 18
years or older than 75 years; 2, use of beta-blockers,
nitrates, anticoagulation drugs, and calcium antagonists
within 24 hours before the study; 3, a known history of
venous insufficiency (including history of previous DVT);
4, unstable angina or myocardial infarction within the pre-
vious 3 months; and 5, diabetes or heart or liver failure.
Male patients were not recruited in this study because of
the rarity of the cases in this population group. Also, it is
known that there are no significant differences in conven-
tional DVT risk factors and no differences in the aggregate
number of risk factors between male and female patients.1
All the patients recruited were postmenopausal. We did
not record the estrogen intake (estrogen replacement) sta-
tus of these women. Estrogen replacement therapy is just
beginning to be promoted in our country, and only a few
women undergo estrogen therapy after menopause.
Induction of anesthesia and monitoring. Standard
monitoring for anesthesia included continuous heart rate
determination via electrocardiogram, noninvasive blood
pressure determinations obtained every 1 to 5 minutes,
and continuous pulse oximetry. Anesthesia was induced
with intravenous thiopental sodium 5 mg/kg, fentanyl cit-
rate 2 g/kg, and atracurium besylate 0.4 mg/kg to facil-
itate mechanical ventilation. Maintenance of anesthesia
was accomplished with isoflurane at end tidal concentra-
tion of 1% to 1.5% in 60% nitrous oxide and 40% oxygen.
Mechanical ventilation was adjusted to maintain normo-
capnia (end tidal CO2, 35 to 45 mm Hg). The tourniquet
occlusion were applied in all of the cases before incisions
were made. All cases underwent unilateral TKA. After
wound closure, the muscle relaxation was reversed with
neostigmine (0.05 mg/kg) and atropine (1 mg). The
endotracheal tube was removed when clinically adequate
spontaneous respiration resumed. 
Collection and processing of blood samples for P-
selectin determination. Whole blood samples for assay-
ing P-selectin were drawn from the radial artery at 1 hour
before induction of anesthesia and in the morning of the
5th postoperative day. Blood samples were stored in 12 
75–mm Falcon polystyrene test tubes that contained a 1:4
volume of acid citrate glucose solution for measurement of
platelet activation markers.
Platelet-rich plasma (PRP) was obtained with centrifu-
gation of the blood at 280g for 15 minutes at room tem-
perature (RT). The platelet suspension was immediately
fixed in excess paraformaldehyde (1% vol/vol, final con-
centration) after collection and incubated for 15 minutes
at RT. Platelets were then pelleted from platelet-rich
plasma with centrifugation at 2200g for 7 minutes and
washed three times with phosphate-buffered saline solu-
tion/ethylenediamine tetraacetic acid (PBS/EDTA). The
washed platelets then were incubated with 20 L of
monoclonal antibodies specific for CD61 and CD62p (P-
selectin, granule membrane protein (GMP) 140,
Pharmingen, Becton Dickinson, Mountainview, Calif).
CD61 is expressed on platelets, megakaryocytes, and
macrophages. The mixture was incubated in the dark at
RT for 30 minutes. Subsequently, the platelets were
washed with PBS/EDTA (3 times), resuspended in 125
L of PBS/EDTA, and placed in the dark for flow cytom-
etry analysis (FACSCAN, Becton Dickinson). 
Flow cytometry. The instrument was equipped with
an argon laser and operated at 15 MW power at a wave-
length of 488 nm fluoroisothiocyanate fluorescence pass
filter. The instrument was calibrated for fluorescence and
light scatter daily with beads (Calibrite, Becton Dickinson).
Cell samples were passed through the laser beam via
cuvettes. Light scatter and fluorescence data were obtained
with gain settings in the logarithmic mode, and the data
were analyzed on a computer with the Consort 30 pro-
gram (Becton Dickinson). The platelets were distinguished
from the other cells on the basis of their forward and 90-
degree light scatter profile.8 Debris or “machine noise” was
excluded from analysis with setting the appropriate for-
ward scatter threshold. A gate was set around the platelets,
and percentage positivity was determined on 10,000
cells/sample. The sensitivity of fluorescence detection was
maintained during and between assays with Immunobrite
fluorospheres (Becton Dickinson).
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Flow cytometry analysis. The two groups were
compared with reference to levels of P-selectin in resting
and activated platelets. Activated platelet was defined as
CD62p+/CD61+ surface expression on platelets. Murine
monoclonal antibodies of subclass immunoglobulin G 1
(CD61), specific for platelet membrane glycoprotein Ib,
were used to identify and enumerate platelets and platelet
aggregates on the basis of their characteristic forward scat-
ter and CD61-fluoroisothiocyanate fluorescence profiles.
Monoclonal antibodies specific for CD62p or P-selectin
were of the immunoglobulin G 1 subclass and recognized a
140-kd glycoprotein that became associated with the
platelet surface during secretion. This 140-kd glycoprotein
was previously designated as a platelet activation–dependent
granule-external membrane protein or GMP 140.
Surveillance for deep vein thrombosis. Surveillance
for DVT was performed in all patients 5 days after TKA
with contrast venogram. The ascending roentgenographic
venography technique was used, with a bolus injection of
contrast medium, via scalp needles inserted in a dorsal
vein. Tourniquets were placed around the lower third of
the calf and around the lower third of the thigh. Six con-
ventional 30  120–cm films were taken while the tourni-
quets were sequentially removed.10,11 If the iliac veins or
the vena cava were not clearly visualized, digitalized
venograms were taken after a distal contrast medium injec-
tion.10 If the vena cava remained nonvisualized, a digital-
ized proximal cavography was performed after a femoral
injection.10 Interpretation was made by one trained radi-
ologist blinded to the results of flow cytometry analysis.
The venographic criteria for the diagnosis of DVT
included both direct signs (direct visualization of a filling
defect within the venous system) and indirect signs (eg,
nonfilling or varicosity changes). Patients in whom DVT
developed after surgery and patients who underwent TKA
but did not have DVT develop were divided into two
groups. None of the patients received prophylaxis therapy
against thrombosis, in any form, whether intermittent
pneumatic compression alone or in combination with
heparin, warfarin, or aspirin.
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Statistical analysis. Mean values ± standard deviation
were used for descriptive statistics. Wilcoxon scores were
obtained with ranking raw scores for each of the platelet
activation markers measured before and after surgery.
Differences between groups were analyzed with the
Mann-Whitney test. A P value of less than .05 was consid-
ered statistically significant. The performance of P-selectin
expression as a diagnostic test is shown in the way of
receiver operating characteristic (ROC) curve (SPSS,
Chicago, Ill).
RESULTS
Demographic data. The study participants consisted
of 52 female patients classified into two groups: one group
with radiologically confirmed DVT and the other group
with no radiologic evidence of DVT. These two groups
did not differ in their demographic data in terms of age,
weight, and pulse rate (Table I). There was also no differ-
ence found between the study groups with respect to pre-
operative hemoglobin level, hematocrit level, platelet
count, prothrombin time, activated partial thromboplastin
time, perioperative blood loss, and time of tourniquet use
during surgery (Table I).
Radiologic screening for deep vein thrombosis.
DVT was radiologically documented on the 5th day after
operation in 19 of the 52 patients (36%) who underwent
TKA with general anesthesia. The remaining 33 of the 52
patients for TKA (64%) had no radiologic evidence of
DVT on the 5th postoperative day. 
Platelet adhesion molecule expression. As a marker
of platelet activation, the number of CD62p-positive cells
was measured at baseline and on the 5th postoperative
day. The percentage of activated (CD62p+) platelets in the
blood samples of patients for TKA without DVT and
patients for TKA with DVT obtained 1 hour before induc-
tion of anesthesia were 1.438% ± 0.92% (n = 33) and
1.099% ± 0.9% (n = 19), respectively (P > .05). Significant
increases in the number of activated platelets were found
in the group in which postoperative DVT developed
(6.57% ± 3.1% versus 1.099% ± 0.9%; P < .05) and in the
Table I. Demographic data of patients for total knee arthroplasty with and without radio-
logic evidence of deep vein thrombosis
Without DVT (n = 33) With DVT (n = 19)
Female gender 33 19
Age (y) 67.2 (7.4) 64.9 (8.6)
Weight (kg) 67 (13) 59 (8)
Blood loss (mL) 83 (75) 130 (150)
Pulse rate (beats/min) 84 (8) 80 (4)
Preoperative platelet count 242,636 (62,335) 251,556 (60,224)
Preoperative hemoglobin level (gm/dL) 12.1 (1.6) 11.7 (1.3)
Preoperative hematocrit level (%) 37 (4.5) 35 (3.8)
Preoperative PT (s) 10.4 (0.7) 10.1 (0.6)
Preoperative APTT (s) 26.5 (3.3) 27.2 (4.4)
Tourniquet time (min) 103.5 (22) 91 (23)
Data are expressed as mean (standard deviation).
DVT, Deep vein thrombosis; PT, prothrombin time; APTT, activated partial thromboplastin time.
group with no DVT after surgery (2.73% ± 0.94% versus
1.438% ± 0.92%; P < .05). However, there was a signifi-
cantly higher amount of activated platelets in patients for
TKA with DVT when compared with patients for TKA
without DVT (6.57% ± 3.1% versus 2.73% ± 0.94%; P <
.01; Table II).
The diagnostic performance of P-selectin assay both
before and after surgery is shown in the form of the ROC
curve (Fig). The diagnostic performance of this CD62p
assay used the cut-off value of 4.3%. CD62p was negative
in five of 19 patients with DVT. Thus, the sensitivity of the
P-selectin assay for the diagnosis of DVT was 14 of 19
(74%), and the specificity was 31 of 33 (94%). Positive pre-
dictive value of CD62p activation was 14 of 16 (87%), and
the negative predictive value was 31 of 36 (86%; Table
III). With the risk of postoperative bleeding, we chose this
point on the ROC curve because, in our country, the risk
of bleeding far outweighs the risk of development of a
thromboembolic event.
DISCUSSION
DVT is an important, treatable complication that
remains to be a major perioperative cause of morbidity and
mortality in patients who undergo major orthopedic
surgery, such as TKA.2 Experiences in the past have shown
that platelet count and bleeding time were not useful in
identifying patients in whom DVT may be developing.
Moreover, clinical risk factors, such as advanced age, obe-
sity, malignant disease, congestive heart failure, acute
myocardial infarction, prior DVT or pulmonary throm-
boembolism, estrogen use, and immobilization have been
poor predictors of the presence of DVT.12 Ultrasound
scan in detecting DVT is highly accurate and readily avail-
able, but it has its limitations in some surgical patients.
False-positive results have been reported to occur in as
much as 6% of patients, and calf DVT may not be readily
detected. Although other reports suggest high positive
and negative predictive values, ultrasound scan is relatively
investigator-dependent and requires certain training.13,14
In a particular study, technetium 99m–labeled tissue
plasminogen activator was used to detect the postopera-
tive DVT.15 Among the detection methods for DVT, con-
trast venography has been used for many years as the gold
standard for the diagnosis of DVT.10 This was the main
reason we adopted contrast venography as our indepen-
dent variable. This procedure, however, is not without
risks. It is quite invasive and requires much technical dex-
terity and may be subject to investigator bias in its diag-
nostic quality. The P-selectin assay that was used in this
study may provide a simple noninvasive procedure that can
detect early changes in the coagulation process that could
lead to the development of DVT.
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Receiver operating characteristic curve of P-selectin assay as
diagnostic test for deep vein thrombosis 5 days after total knee
arthroplasty.
A
B
Table II. Platelet CD62p expression in patients for total
knee arthroplasty with and without deep vein thrombosis
Without DVT With DVT
(n = 33) (n = 19)
Preoperative CD62p 1.44% (0.92%) 1.1% (0.91%)
Postoperative CD62p 2.72% (0.94%)† 6.57% (3.1%)*†
Data are expressed as mean (standard deviation).
*Significantly different from patients without DVT (P < .05).
†Significantly different from preoperative values (P < .05).
DVT, Deep vein thrombosis.
Alterations in the coagulation cascade appear to involve
platelet activation, the triggering of the coagulation cas-
cade, and the blunting of endogenous fibrinolytic activity in
DVT, which have been reported to be involved in the
changes of coagulation in patients who undergo knee
arthroplasty.7,16 This was the first study to show that
platelet abnormalities (platelet activation) may be important
contributing or associated factors leading to the higher inci-
dence of postoperative DVT in patients who undergo TKA.
There are a number of methods used for the assess-
ment of platelet activation that include -thromboglobulin
and thromboxane A2 functional assays, platelet aggregom-
etry, and radiolabeled fibrinogen assays.17 However, these
are often technically difficult to quantitate and have prob-
lems in defining platelet function clinically. In this study,
flow cytometry was used for the analysis of changes in the
expression of platelet membrane glycoproteins. Flow
cytometry lends itself well to methodologic objectivity.
The use of CD62p as a marker for platelet activation is also
appropriate because its surface expression correlates with
the release of -granule content and it is also not reinter-
nalized after secretion. In addition, previous reports have
shown a parallel change in the expression of the plasma
membrane glycoproteins Ib, IIIa, CD31, CD63, and
CD62p antigen after stimulation of platelets in vitro and in
vivo.18 Thus, changes in the levels of expression of the
platelet activation–dependent antigen CD62p may be used
as diagnostic markers in determining susceptibility to DVT
during TKA. Our study suggests that P-selectin activation
marker may be used as one of the parameters or one means
for the early detection of development of DVT.
The incidence rate of DVT we reported here was 36%
in patients for TKA, with no gender difference because
only female patients were recruited in this study. Although
the incidence rate of DVT in this study was higher than
previously reported in Taiwan, it is still below the fre-
quency observed in Western populations (40% to
88%).19,20 In these Western countries, prophylaxis for
DVT in the form of heparin is the standard of practice in
institutions performing TKA. However, the incidence rate
of major bleeding complications has been reported to be
2.8% (20 of 715 patients) in the low–molecular-weight
heparin group.6 In our society, the public expectation is
such that a surgeon would not risk the possibility of bleed-
ing complication to avoid the development of DVT.
In our study, when we assayed for platelet activation
and compared the obtained levels with radiographic DVT
diagnosis, we calculated that P-selectin activation of less
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than 4.3% had predicted the absence of DVT in 86% of
patients for TKA. In contrast, platelet activation of more
than 4.3% predicted the presence of DVT in 87% of the
patients for TKA. The sensitivity of the P-selectin assay for
the diagnosis of DVT was calculated to be 74%, and the
specificity was determined to be 94%. According to a pre-
vious report, sensitivity of venography in the diagnosis of
overall DVT is 92% and its specificity is 94.1%.10 Our data
have shown that an increase in the percentage of platelets
expressing CD62p (GMP 140) may offer a quick and easy
test to confirm DVT. The platelet count and the bleeding
time have not been found to have discriminating potential,
whereas circulating platelets expressing CD62p antigen
related to venous thrombosis induced after TKA have
been found to have this discriminating potential.
Underestimation of platelet activation as a result of
binding to other cells has been suggested in previous
descriptions of platelet flow cytometry.21 It is possible that
our method may have underestimated the true percentage
of particles staining positive for the platelet marker
because some of these platelets may have been adhering to
neutrophils in the platelet rich plasma.7,22 However,
despite that, our method (which ignores the platelet-neu-
trophil complexes) may still be ideally and simply suited to
the investigation of the relative number of platelet activa-
tion in DVT. So, the platelet-neutrophil complexes did
not appear to be confounding factors in our methodology
in determining the percentage of the platelet activation. D
dimer analysis has been shown in previous studies to have
a high specificity (92%) but a low sensitivity (37%) in the
diagnosis of DVT.11 In comparison with D dimer forma-
tion, increased expression of P-selectin with flow cytome-
try may provide an early, more sensitive, and equally
specific marker of DVT development.23
Overall, the data from this study showed that the ele-
vated CD62p marker (which reflects the number of acti-
vated platelets) may be useful in predicting the incidence
of DVT in patients who undergo TKA. Platelet activation
is a major factor in thrombus formation, and continuing
platelet activation is possibly associated with an adverse
prognosis. Whether current noninvasive cytometry meth-
ods for detecting platelet activation should be gradually
substituted for venography in patients for TKA, however,
remains to be seen. The data generated from this study
could be used in eventually developing a panel of diag-
nostic protocols that could be recommended in monitor-
ing development of DVT among patients for TKA. The
clinical implications of these data are unknown at this
Table III. Relation between CD62p expression and deep vein thrombosis
With DVT Without DVT Total
With CD62p 14 2 16
Without CD62p 5 31 36
Total 19 33 52
DVT, Deep vein thrombosis.
time. However, assessment of platelet activation with P-
selectin changes may provide a rationale for effective early
therapeutic regimens in the future. Other experiments are
underway to show the anatomic distribution, severity, and
levels of DVT that could be preexisting in our patients for
TKA to determine the correlation between these factors
and levels of P-selectin activation. We shall also try to
define other risk factors for DVT by establishing the gene
bank of patients with DVT in Taiwan to understand bet-
ter the prevalence of factor V Leiden, antiphospholipid
antibodies, and prothrombin gene 20210 mutations.24-26
We thank Prof Nina Gloriani Barzaga for reading and
editing the manuscript and Dr Shun-Jen Chang,
Department of Public Health, Kaohsiung Medical
University, for assistance with statistical analysis.
REFERENCES
1. Beebe HG, Scissons RP, Salles-Cunha SX, Dosick SM, Whalen RC,
Gale SS, et al. Gender bias in use of venous ultrasonography for diag-
nosis of deep venous thrombosis. J Vasc Surg 1995;22:538-42.
2. Leiberman JR, Geerts WH. Prevention of venous thromboembolism
after total hip and knee arthroplasty. J Bone Joint Surg Am 1994;76A:
1239-50.
3. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal
pulmonary embolism in patients with treated venous thromboem-
bolism. JAMA 1998;279:458-62. 
4. Solis MM, Ranval TJ, Nix ML, Eidt JF, Nelson CL, Ferris EJ, et al. Is
anticoagulation indicated for asymptomatic postoperative calf vein
thrombosis? J Vasc Surg 1992;16:414-8.
5. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas
EM, et al. Thrombo-embolic prophylaxis in total knee replacement.
Evaluation of the A-V impulse system. J Bone Joint Surg Br
1992;74:50-2.
6. Hull R, Raskob G, Rosenbloom D, Evans W, Mallory T, Anquist K,
et al. A comparison of subcutaneous low-molecular-weight heparin
with warfarin sodium for prophylaxis against deep-vein thrombosis
after hip or knee implantation. N Engl J Med 1993;329:1370-6. 
7. Comerota AJ, Stewart GJ, White JV. Combined dihydroergotamine
and heparin prophylaxis of postoperative deep vein thrombosis: pro-
posed mechanism of action. Am J Surg 1985;150:39-44.
8. Gemmell CH, Yeo EL, Sefton MV. Flow cytometric analysis of material-
induced platelet activation in a canine model: elevated microparticle lev-
els and reduced platelet life span. J Biomed Mater Res 1997;37:176-81. 
9. Cahill MR, Macey MG, Newland AC. Fixation with formaldehyde
induces expression of activation dependent platelet membrane glyco-
proteins, P selectin (CD62) and GP53 (CD63). Br J Haematol
1993;84:527-9.
10. Lensing AW, Buller HR, Prandoni P, Batchelor D, Molenaar AH,
Cogo A, et al. Contrast venography, the gold standard for the diag-
nosis of DVT: improvement in observer agreement. Thromb
Haemost 1992;67:8-12.
11. Leroyer C, Escoffre M, Le Moigne E, Grimaux M, Cagnioncle O,
Oger E, et al. Diagnostic value of a new sensitive membrane based
technique for instantaneous D-dimer evaluation in patients with clin-
ically suspected deep venous thrombosis. Thromb Haemost 1997;
77:637-40.
12. Criado E, Burnham CB. Predictive value of clinical criteria for the
diagnosis of deep vein thrombosis. Surgery 1997;122:578-83.
13. Davidson HC, Mazzu D, Gage BF, Jeffrey RB. Screening for deep
venous thrombosis in asymptomatic postoperative orthopedic patients
using color Doppler sonography: analysis of prevalence and risk fac-
tors. AJR Am J Roentgenol 1996;166:659-62.
14. Zhang GJ, Adachi I, Duan Z, Zhang Q, Guo R, Tang L, et al. The
accuracy of color Doppler flow imaging for the detection of sympto-
matic deep venous thrombosis in Chinese patients. Surg Today
1996;26:683-5.
15. Butler SP, Rahman T, Boyd SJ, Parkes SL, Quinn RJ. Detection of
postoperative deep-venous thrombosis using technetium-99m-labeled
tissue plasminogen activator. J Nucl Med 1997;38:219-23.
16. Daniel S, O’Brien JR, John JA. Platelets in the prediction of throm-
botic risk. Atherosclerosis 1982;45:91-9.
17. Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EW Jr. Molecular
markers of hemostatic disorders: implications in the diagnosis and
therapeutic management of thrombotic and bleeding disorders. Clin
Chem 1983;29:1641-58. 
18. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH,
Nieuwenhuis HK, Roos D, et al. Detection of platelet activation with
monoclonal antibodies and flow cytometry. Transfusion 1990;30:20-5. 
19. Lee HC, Liao WB, Bullard MJ, Hsu TS. Deep venous thrombosis in
Taiwan. Jpn Heart J 1996;37:891-6.
20. Guyton JL. Arthroplasty of ankle and knee. In: Canale ST, ed.
Campbell’s operative orthopaedics. St Louis: Mosby; 1998.
21. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets
in whole blood using activation-dependent monoclonal antibodies
and flow cytometry. Blood 1987;70:307-15.
22. Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Kansas
GS, Snapp KR, et al. Venous levels of shear support neutrophil-
platelet adhesion and neutrophil aggregation in blood via P-selectin
and beta2-integrin. Circulation 1998;98:873-82.
23. Meissner MH, Zierler BK, Bergelin RO, Chandler WC, Manzo RA,
Strandness DE. Markers of plasma coagulation and fibrinolysis after
acute deep venous thrombosis. J Vasc Surg 2000;32:870-80.
24. Rosendall FR, Koster T, Vandenbroucke JP, Reitsma DP. High risk of
thrombosis in patients homozygous for factor V (activated protein C
resistance). Blood 1995;270:2158-66.
25. Ginsberg JS, Wells PS, Brill Edwards P. Antiphospholipid antibodies
and venous thromboembolism. Blood 1995;86:3685-91.
26. Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common
genetic variation in 3-untranslated region of prothrombin gene is
associated with elevated plasma prothrombin levels and an increase in
venous thrombosis. Blood 1996;88:3698-703.
Submitted Aug 8, 2001; accepted Oct 22, 2001.
Additional material for this article may be found online
at www.mosby.com/jvs.
JOURNAL OF VASCULAR SURGERY
712 Yang et al April 2002
